Cholesterol drug widens GP options

GPs in Scotland have access to a wider choice of treatments for cholesterol disorders, after the Scottish Medicines Consortium (SMC) approved the combination drug Tredaptive.

The decision means the therapy is available for restricted use in the NHS in Scotland.

Tredaptive contains extended release nicotinic acid 1g and the anti-flushing treatment laropiprant 20mg. GPs can prescribe the drug to treat dyslipidaemia, mixed dyslipidaemia and hypercholesterolaemia in patients for whom statins are not tolerated.

This is the first nicotinic acid formulation accepted by the SMC. In trials, the drug cut LDL cholesterol by 18 per cent and triglycerides by 26 per cent, while raising HDL cholesterol by 20 per cent (placebo adjusted).

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus